MADRIGAL PHARMACEUTICALS, INC. Operating Cash Flow
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Operating Cash Flow of -$144.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $23.33M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$167.44M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$133.46M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $79.85M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$189.55M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$455.57M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$324.23M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$224.86M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$144.11M 10-Q · filed 2026-07-30 | -$277.57M derived: sum of 3 quarters · filed 2026-07-30 | -$197.72M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$167.44M 10-Q · filed 2026-05-06 | -$300.89M derived: sum of 2 quarters · filed 2026-05-06 | -$221.04M derived: sum of 3 quarters · filed 2026-05-06 | -$268.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$133.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$53.61M derived: sum of 2 quarters · filed 2026-02-19 | -$100.66M derived: sum of 3 quarters · filed 2026-07-30 | -$189.55M 10-K · filed 2026-02-19 |
| 2025-09-30 | $79.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $32.80M derived: sum of 2 quarters · filed 2026-07-30 | -$56.09M 10-Q · filed 2025-11-04 | -$160.58M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$47.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$135.94M 10-Q · filed 2026-07-30 | -$240.43M derived: sum of 3 quarters · filed 2026-07-30 | -$307.41M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$88.89M 10-Q · filed 2026-05-06 | -$193.38M derived: sum of 2 quarters · filed 2026-05-06 | -$260.36M derived: sum of 3 quarters · filed 2026-05-06 | -$395.31M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$104.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$171.47M derived: sum of 2 quarters · filed 2026-02-19 | -$306.42M derived: sum of 3 quarters · filed 2026-02-19 | -$455.57M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$66.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$201.93M derived: sum of 2 quarters · filed 2025-11-04 | -$351.09M 10-Q · filed 2025-11-04 | -$431.02M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$134.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$284.10M 10-Q · filed 2025-08-05 | -$364.04M derived: sum of 3 quarters · filed 2026-02-19 | -$448.95M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$149.16M 10-Q · filed 2025-05-01 | -$229.09M derived: sum of 2 quarters · filed 2026-02-19 | -$314.01M derived: sum of 3 quarters · filed 2026-02-19 | -$389.32M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$79.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$164.85M derived: sum of 2 quarters · filed 2026-02-19 | -$240.16M derived: sum of 3 quarters · filed 2026-02-19 | -$324.23M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$84.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$160.23M derived: sum of 2 quarters · filed 2024-10-31 | -$244.30M 10-Q · filed 2024-10-31 | -$302.81M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$75.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$159.38M 10-Q · filed 2024-08-07 | -$217.89M derived: sum of 3 quarters · filed 2025-02-26 | -$276.96M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$84.07M 10-Q · filed 2024-05-07 | -$142.58M derived: sum of 2 quarters · filed 2025-02-26 | -$201.65M derived: sum of 3 quarters · filed 2025-02-26 | -$259.01M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$58.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$117.58M derived: sum of 2 quarters · filed 2025-02-26 | -$174.94M derived: sum of 3 quarters · filed 2025-02-26 | -$224.86M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$59.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$116.43M derived: sum of 2 quarters · filed 2023-11-06 | -$166.34M 10-Q · filed 2023-11-06 | -$214.39M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$57.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$107.27M 10-Q · filed 2023-08-08 | -$155.32M derived: sum of 3 quarters · filed 2024-02-28 | -$200.88M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$49.91M 10-Q · filed 2023-05-09 | -$97.96M derived: sum of 2 quarters · filed 2024-02-28 | -$143.52M derived: sum of 3 quarters · filed 2024-02-28 | -$190.40M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$48.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$93.61M derived: sum of 2 quarters · filed 2024-02-28 | -$140.49M derived: sum of 3 quarters · filed 2024-02-28 | -$183.92M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$45.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$92.44M derived: sum of 2 quarters · filed 2022-11-03 | -$135.87M 10-Q · filed 2022-11-03 | -$190.81M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | -$46.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$90.31M 10-Q · filed 2022-08-04 | -$145.26M derived: sum of 3 quarters · filed 2023-03-03 | -$193.11M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | -$43.43M 10-Q · filed 2022-05-09 | -$98.38M derived: sum of 2 quarters · filed 2023-03-03 | -$146.23M derived: sum of 3 quarters · filed 2023-03-03 | -$170.48M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | -$54.95M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | -$102.80M derived: sum of 2 quarters · filed 2023-03-03 | -$127.06M derived: sum of 3 quarters · filed 2023-03-03 | -$157.56M 10-K/A · filed 2023-03-03 |
| 2020-09-30 | -$47.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$72.11M derived: sum of 2 quarters · filed 2021-11-04 | -$102.61M 10-Q · filed 2021-11-04 | -$114.90M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$24.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$54.76M 10-Q · filed 2021-08-05 | -$67.05M derived: sum of 3 quarters · filed 2022-02-24 | -$78.37M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$30.51M 10-Q · filed 2021-05-06 | -$42.79M derived: sum of 2 quarters · filed 2022-02-24 | -$54.11M derived: sum of 3 quarters · filed 2022-02-24 | -$65.65M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$12.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$23.61M derived: sum of 2 quarters · filed 2022-02-24 | -$35.15M derived: sum of 3 quarters · filed 2022-02-24 | -$41.62M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$11.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$22.86M derived: sum of 2 quarters · filed 2020-11-05 | -$29.34M 10-Q · filed 2020-11-05 | -$35.61M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$11.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$18.02M 10-Q · filed 2020-08-06 | -$24.28M derived: sum of 3 quarters · filed 2021-02-25 | -$29.52M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$6.48M 10-Q · filed 2020-05-07 | -$12.74M derived: sum of 2 quarters · filed 2021-02-25 | -$17.98M derived: sum of 3 quarters · filed 2021-02-25 | -$23.34M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$6.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$11.50M derived: sum of 2 quarters · filed 2021-02-25 | -$16.86M derived: sum of 3 quarters · filed 2021-02-25 | -$25.51M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$5.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$10.60M derived: sum of 2 quarters · filed 2019-11-06 | -$19.24M 10-Q · filed 2019-11-06 | -$25.19M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | -$5.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$14.00M 10-Q · filed 2019-08-07 | -$19.95M derived: sum of 3 quarters · filed 2020-02-26 | -$24.90M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | -$8.64M 10-Q · filed 2019-05-08 | -$14.59M derived: sum of 2 quarters · filed 2020-02-26 | -$19.54M derived: sum of 3 quarters · filed 2020-02-26 | -$27.19M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | -$5.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$10.90M derived: sum of 2 quarters · filed 2020-02-26 | -$18.55M derived: sum of 3 quarters · filed 2020-02-26 | -$22.32M 10-K · filed 2020-02-26 |
| 2017-09-30 | -$4.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$12.60M derived: sum of 2 quarters · filed 2018-11-06 | -$16.37M 10-Q · filed 2018-11-06 | -$21.65M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | -$7.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$11.42M 10-Q · filed 2018-08-07 | -$16.70M derived: sum of 3 quarters · filed 2019-02-27 | -$25.94M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | -$3.77M 10-Q · filed 2018-05-08 | -$9.05M derived: sum of 2 quarters · filed 2019-02-27 | -$18.29M derived: sum of 3 quarters · filed 2019-02-27 | |
| 2016-12-31 | -$5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$14.52M derived: sum of 2 quarters · filed 2019-02-27 | -$17.61M 10-K · filed 2019-02-27 | |
| 2016-09-30 | -$9.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$12.33M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | -$3.08M 10-Q · filed 2017-08-10 | |||
| 2011-06-30 | -$24.99M 10-Q · filed 2011-08-04 | |||
| 2010-06-30 | -$21.56M 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |